Good morning :)
Place Order
Add to Watchlist

Gland Pharma Ltd

GLAND

Gland Pharma Ltd

GLAND
Health CarePharmaceuticals
SmallcapWith a market cap of ₹29,669 cr, stock is ranked 268
Moderate RiskStock is 2.33x as volatile as Nifty
1,813.251.14% (-20.95)
1,813.251.14% (-20.95)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹29,669 cr, stock is ranked 268
Moderate RiskStock is 2.33x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹29,669 cr, stock is ranked 268
Moderate RiskStock is 2.33x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
42.903.401.11%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
56%
Analysts have suggested that investors can buy this stock

from 9 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue2,772.413,597.664,624.653,865.065,834.966,080.78
Raw Materialssubtract1,108.931,765.362,072.531,732.342,045.204,613.66
Power & Fuel Costsubtract78.5074.5995.05124.84229.99
Employee Costsubtract277.66311.36338.57403.261,256.89
Selling & Administrative Expensessubtract98.54128.48177.92187.93286.86
Operating & Other expensessubtract114.15-119.14206.49207.92512.71
Depreciation/Amortizationsubtract94.5998.78110.30146.74344.57383.74
Interest & Other Itemssubtract7.183.415.247.4526.2026.97
Taxes & Other Itemssubtract220.01337.85406.89273.54360.08364.84
EPS49.8862.6073.9147.4846.9041.99
DPS0.000.000.000.0020.0020.00
Payout ratio0.000.000.000.000.430.48

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 19PDF
Jan 21PDF
Oct 22PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

May 18PDF
Jan 23PDF
Oct 26PDF
Jul 20PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 7PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Gland Pharma Ltd38.413.401.11%
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare GLAND with any stock or ETF
Compare GLAND with any stock or ETF
GLAND
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 6.02%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Decreased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 2.41%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding51.83%32.83%2.54%4.47%8.32%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep2.80%4.91%4.04%3.59%6.88%4.47%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 2.30%

Top 5 Mutual Funds holding Gland Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan

Growth
3.0896%1.22%-0.36%32/79 (-7)
Mirae Asset Large & Midcap Fund - Growth - Direct Plan

Growth
2.0520%1.60%-0.29%14/105 (-3)
SBI Large & Midcap Fund - Growth - Direct Plan

Growth
1.6988%1.72%0.41%12/85 (+20)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 16, 2024

Final
Final | Div/Share: ₹20.00

Dividend/Share

20.00

Ex DateEx Date

Aug 16, 2024

News & Opinions
Spotlight
Gland Pharma Ltd spurts 1.67%, rises for third straight session

Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1809.85, up 1.67% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Gland Pharma Ltd has added around 12.35% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 1.11 lakh shares today, compared to the daily average of 4.86 lakh shares in last one month.The PE of the stock is 26.58 based on TTM earnings ending September 24.Powered by Capital Market - Live

5 days agoCapital Market - Live
Spotlight
Gland Pharma rises on USFDA nod for ophthalmic solution

The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan, Latanoprost Ophthalmic Solution held by UPJOHN US 2 LLC. This product is used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with openangle glaucoma or ocular hypertension. The drug maker expects to launch this product through its marketing partners in FY25. According to IQVIA, the product had US sales of approximately $111.6 million for the twelve months ending December 2023. Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

5 days agoCapital Market - Live
Spotlight
Volumes jump at Gland Pharma Ltd counter

Chemplast Sanmar Ltd, Hatsun Agro Product Ltd, ABB India Ltd, Bata India Ltd are among the other stocks to see a surge in volumes on BSE today, 05 November 2024.Gland Pharma Ltd saw volume of 47247 shares by 10:47 IST on BSE, a 10.69 fold spurt over two-week average daily volume of 4421 shares. The stock increased 9.75% to Rs.1,766.80. Volumes stood at 6858 shares in the last session.Chemplast Sanmar Ltd recorded volume of 36259 shares by 10:47 IST on BSE, a 5.59 times surge over two-week average daily volume of 6484 shares. The stock gained 4.70% to Rs.497.00. Volumes stood at 7142 shares in the last session.Hatsun Agro Product Ltd witnessed volume of 12872 shares by 10:47 IST on BSE, a 4.76 times surge over two-week average daily volume of 2704 shares. The stock increased 9.17% to Rs.1,160.15. Volumes stood at 9414 shares in the last session.ABB India Ltd recorded volume of 37866 shares by 10:47 IST on BSE, a 4.45 times surge over two-week average daily volume of 8510 shares. The stock lost 3.97% to Rs.7,069.90. Volumes stood at 9507 shares in the last session.Bata India Ltd notched up volume of 43257 shares by 10:47 IST on BSE, a 3.69 fold spurt over two-week average daily volume of 11733 shares. The stock rose 0.59% to Rs.1,344.75. Volumes stood at 15468 shares in the last session.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Gland Pharma soars as Q2 PAT rises 9% YoY to Rs 282 cr

On consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore on 2.36% to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. Profit before tax (PBT) stood at Rs 256.78 crore, down 11.42% as compared with Rs 289.89 crore in second quarter of FY24. For Q2 of FY25, EBITDA was Rs 296.1 crore, registering de-growth of 8%. EBITDA margin reduced from 21% to 23% during the quarter. Revenue from US market stood at Rs 754.7 crore (up 3% YoY), revenue Europe was at Rs 245.9 crore (down 1% YoY), Canada, Australia and New Zealand stood at Rs 51.5 crore (up 45% YoY) while revenue from India was at Rs 87.4 crore and Rest of the world was at Rs 266.3 crore during the period under review. Total capex incurred during the quarter was Rs 103.7 crore. R&D expenses stood at Rs 49.3 crore in Q2 of FY25, (4.6% of revenue). Cenexi's gross profit shed 15% YoY to Rs 234.7 crore and revenue from operations decreased 5% YoY to Rs 339.9 crore during the quarter. On outlook front, the company said that despite the near-term headwinds, it continued to strive to achieve short-term outlook: a positive EBITDA for Q4 of FY25. It maintains goal of a positive EBITDA for the next fiscal year, driven by an increase in revenue above the '200 million threshold. Srinivas Sadu, executive chairman and CEO of Gland Pharma, said, 'We had a good first half of 2025 and are on course to achieve our outcomes for the full year. This quarter, we reported Rs 14,058 million in revenue and Rs 2,961 million in EBITDA, representing a 21% EBITDA margin. Although our overall EBITDA margin was affected by Cenexi, our base business maintained a steady 34% EBITDA margin. Our core regulated markets, particularly the United States, continue to perform well. Our overall performance is in line with expectations. Looking ahead, we remain focused on our strategic priorities, which include entering new markets and building a solid foundation for future growth.' Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Gland Pharma consolidated net profit declines 15.74% in the September 2024 quarter

Net profit of Gland Pharma declined 15.74% to Rs 163.53 crore in the quarter ended September 2024 as against Rs 194.08 crore during the previous quarter ended September 2023. Sales rose 2.36% to Rs 1405.83 crore in the quarter ended September 2024 as against Rs 1373.42 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1405.831373.42 2 OPM %21.1323.60 - PBDT350.60371.19 -6 PBT256.78289.89 -11 NP163.53194.08 -16 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Gland Pharma to hold board meeting

Gland Pharma will hold a meeting of the Board of Directors of the Company on 4 November 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Gland Pharma Ltd slips for fifth straight session

Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1809, down 1.76% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.06% on the day, quoting at 25392.05. The Sensex is at 83172.83, up 0.27%.Gland Pharma Ltd has lost around 6.26% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 2.13% in last one month and is currently quoting at 23025.2, down 0.76% on the day. The volume in the stock stood at 77964 shares today, compared to the daily average of 3.85 lakh shares in last one month.The PE of the stock is 28.14 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Gland Pharma Ltd gains for third straight session

Gland Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1936.35, up 1.59% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.02% on the day, quoting at 24856.05. The Sensex is at 81295.07, up 0.14%. Gland Pharma Ltd has slipped around 4.99% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has slipped around 3.48% in last one month and is currently quoting at 23043.4, down 0.28% on the day. The volume in the stock stood at 3.79 lakh shares today, compared to the daily average of 4.18 lakh shares in last one month.The PE of the stock is 29.1 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Gland Pharma slides after Q1 PAT slumps 26% YoY to Rs 144 cr

Revenue from operations jumped 15.97% YoY to Rs 1,401.70 crore in Q1 FY25. Profit before tax (PBT) stood at Rs 218.24 crore, down 16.47% as compared with Rs 261.26 crore in Q1 FY24. EBITDA fell to Rs 265.4 crore during the quarter as compared with Rs 298.2 crore in Q1 FY23, registering de-growth of 11%. EBITDA margin reduced from 25% to 19% during the quarter. Revenue from US market stood at Rs 762.8 crore (up 27% YoY), revenue Europe was at Rs 256.6 crore (up 15% YoY), Canada, Australia and New Zealand stood at Rs 44.7 crore (up 72% YoY) while revenue from India was at Rs 52.7 crore (down 19% YoY) and Rest of the world was at Rs 284.9 crore (down 3% YoY) during the period under review. Total capex incurred during the quarter was Rs 63.7 crore. R&D expenses stood at Rs 48.9 crore in Q1 FY25, (5% of revenue). Cenexi's gross profit jumped 24% to Rs 302.6 crore during the quarter as comapred with Rs 243.6 crore in Q1 FY24. Revenue from operations increased 21% YoY to Rs 388.3 crore during the quarter. On outlook front, the company said that In Q2 FY25 Lower activity levels are expected due to the European holiday season and planned summer maintenance shutdowns. The Fontenay plant will have an extended 3-week shutdown for new ampoule line installation. It expects positive EBITDA for Q4 of this fiscal year and a positive EBITDA for the next fiscal year, driven by increased revenue exceeding the '200 million threshold. Srinivas Sadu, executive chairman and CEO of Gland Pharma, said, 'We reached Rs 1,401.7 crore in total revenue, a 16% increase from Q1FY24. This growth aligns with our projections and is primarily driven by the US market, which saw a 27% revenue increase led by existing and certain new products. Our base business EBITDA margins were at 29%, and consolidated EBITDA margins for the quarter were 19%, mainly affected by Cenexi. We're confident in our ability to meet our fiscal year goals and are excited about the growing opportunities and even stronger results expected in the coming quarters.' Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Gland Pharma consolidated net profit declines 25.94% in the June 2024 quarter

Net profit of Gland Pharma declined 25.94% to Rs 143.76 crore in the quarter ended June 2024 as against Rs 194.10 crore during the previous quarter ended June 2023. Sales rose 15.97% to Rs 1401.71 crore in the quarter ended June 2024 as against Rs 1208.69 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1401.711208.69 16 OPM %18.8624.32 - PBDT310.21326.58 -5 PBT218.25261.27 -16 NP143.76194.10 -26 Powered by Capital Market - Live

4 months agoCapital Market - Live